Browse ELMO2

Summary
SymbolELMO2
Nameengulfment and cell motility 2
Aliases ELMO-2; KIAA1834; FLJ11656; engulfment and cell motility 2 (ced-12 homolog, C. elegans); PH domain protein C ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Cytoplasm, cytosol Membrane
Domain PF11841 Domain of unknown function (DUF3361)
PF04727 ELMO/CED-12 family
PF16457 Pleckstrin homology domain
Function

Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic cells and cell motility. Acts in association with DOCK1 and CRK. Was initially proposed to be required in complex with DOCK1 to activate Rac Rho small GTPases. May enhance the guanine nucleotide exchange factor (GEF) activity of DOCK1.

> Gene Ontology
 
Biological Process GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002431 Fc receptor mediated stimulatory signaling pathway
GO:0002433 immune response-regulating cell surface receptor signaling pathway involved in phagocytosis
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0006909 phagocytosis
GO:0038093 Fc receptor signaling pathway
GO:0038094 Fc-gamma receptor signaling pathway
GO:0038096 Fc-gamma receptor signaling pathway involved in phagocytosis
GO:0048010 vascular endothelial growth factor receptor signaling pathway
GO:0060326 cell chemotaxis
Molecular Function GO:0017124 SH3 domain binding
GO:0030971 receptor tyrosine kinase binding
GO:1990782 protein tyrosine kinase binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-8849471: PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
R-HSA-2029482: Regulation of actin dynamics for phagocytic cup formation
R-HSA-162582: Signal Transduction
R-HSA-8848021: Signaling by PTK6
R-HSA-194138: Signaling by VEGF
R-HSA-4420097: VEGFA-VEGFR2 Pathway
Summary
SymbolELMO2
Nameengulfment and cell motility 2
Aliases ELMO-2; KIAA1834; FLJ11656; engulfment and cell motility 2 (ced-12 homolog, C. elegans); PH domain protein C ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ELMO2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolELMO2
Nameengulfment and cell motility 2
Aliases ELMO-2; KIAA1834; FLJ11656; engulfment and cell motility 2 (ced-12 homolog, C. elegans); PH domain protein C ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ELMO2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.52; FDR: 0.04180 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolELMO2
Nameengulfment and cell motility 2
Aliases ELMO-2; KIAA1834; FLJ11656; engulfment and cell motility 2 (ced-12 homolog, C. elegans); PH domain protein C ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ELMO2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3230.108
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1540.933
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4490.747
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0180.931
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0160.994
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0230.993
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.040.91
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0370.982
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0150.994
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6910.635
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1950.572
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0070.9
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ELMO2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolELMO2
Nameengulfment and cell motility 2
Aliases ELMO-2; KIAA1834; FLJ11656; engulfment and cell motility 2 (ced-12 homolog, C. elegans); PH domain protein C ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ELMO2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolELMO2
Nameengulfment and cell motility 2
Aliases ELMO-2; KIAA1834; FLJ11656; engulfment and cell motility 2 (ced-12 homolog, C. elegans); PH domain protein C ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ELMO2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ELMO2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolELMO2
Nameengulfment and cell motility 2
Aliases ELMO-2; KIAA1834; FLJ11656; engulfment and cell motility 2 (ced-12 homolog, C. elegans); PH domain protein C ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ELMO2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolELMO2
Nameengulfment and cell motility 2
Aliases ELMO-2; KIAA1834; FLJ11656; engulfment and cell motility 2 (ced-12 homolog, C. elegans); PH domain protein C ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ELMO2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolELMO2
Nameengulfment and cell motility 2
Aliases ELMO-2; KIAA1834; FLJ11656; engulfment and cell motility 2 (ced-12 homolog, C. elegans); PH domain protein C ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ELMO2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolELMO2
Nameengulfment and cell motility 2
Aliases ELMO-2; KIAA1834; FLJ11656; engulfment and cell motility 2 (ced-12 homolog, C. elegans); PH domain protein C ......
Chromosomal Location20q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ELMO2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.